Incyte's cash cow Jakafi chugs along with positive frontline results for GVHD
Five months after the FDA approved Incyte to expand its flagship Jakafi drug to patients with steroid-refractory acute graft-versus-host disease (GVHD), the company announced positive …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
